S&P 500   4,666.36 (+1.56%)
DOW   35,211.71 (+0.90%)
QQQ   399.93 (+2.23%)
AAPL   160.63 (+2.44%)
MSFT   337.76 (+2.45%)
FB   339.24 (+1.84%)
GOOGL   2,912.42 (+2.42%)
AMZN   3,591.39 (+2.48%)
TSLA   1,131.76 (+4.61%)
NVDA   328.76 (+4.36%)
BABA   131.35 (-1.50%)
NIO   40.04 (+0.13%)
CGC   11.10 (-5.05%)
AMD   159.64 (+3.12%)
GE   98.74 (+0.92%)
MU   85.27 (+2.22%)
T   24.02 (-0.83%)
F   19.75 (+0.00%)
DIS   147.52 (-0.40%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   53.83 (-0.31%)
BA   197.47 (-0.87%)
S&P 500   4,666.36 (+1.56%)
DOW   35,211.71 (+0.90%)
QQQ   399.93 (+2.23%)
AAPL   160.63 (+2.44%)
MSFT   337.76 (+2.45%)
FB   339.24 (+1.84%)
GOOGL   2,912.42 (+2.42%)
AMZN   3,591.39 (+2.48%)
TSLA   1,131.76 (+4.61%)
NVDA   328.76 (+4.36%)
BABA   131.35 (-1.50%)
NIO   40.04 (+0.13%)
CGC   11.10 (-5.05%)
AMD   159.64 (+3.12%)
GE   98.74 (+0.92%)
MU   85.27 (+2.22%)
T   24.02 (-0.83%)
F   19.75 (+0.00%)
DIS   147.52 (-0.40%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   53.83 (-0.31%)
BA   197.47 (-0.87%)
S&P 500   4,666.36 (+1.56%)
DOW   35,211.71 (+0.90%)
QQQ   399.93 (+2.23%)
AAPL   160.63 (+2.44%)
MSFT   337.76 (+2.45%)
FB   339.24 (+1.84%)
GOOGL   2,912.42 (+2.42%)
AMZN   3,591.39 (+2.48%)
TSLA   1,131.76 (+4.61%)
NVDA   328.76 (+4.36%)
BABA   131.35 (-1.50%)
NIO   40.04 (+0.13%)
CGC   11.10 (-5.05%)
AMD   159.64 (+3.12%)
GE   98.74 (+0.92%)
MU   85.27 (+2.22%)
T   24.02 (-0.83%)
F   19.75 (+0.00%)
DIS   147.52 (-0.40%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   53.83 (-0.31%)
BA   197.47 (-0.87%)
S&P 500   4,666.36 (+1.56%)
DOW   35,211.71 (+0.90%)
QQQ   399.93 (+2.23%)
AAPL   160.63 (+2.44%)
MSFT   337.76 (+2.45%)
FB   339.24 (+1.84%)
GOOGL   2,912.42 (+2.42%)
AMZN   3,591.39 (+2.48%)
TSLA   1,131.76 (+4.61%)
NVDA   328.76 (+4.36%)
BABA   131.35 (-1.50%)
NIO   40.04 (+0.13%)
CGC   11.10 (-5.05%)
AMD   159.64 (+3.12%)
GE   98.74 (+0.92%)
MU   85.27 (+2.22%)
T   24.02 (-0.83%)
F   19.75 (+0.00%)
DIS   147.52 (-0.40%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   53.83 (-0.31%)
BA   197.47 (-0.87%)
NASDAQ:SONN

Sonnet BioTherapeutics Stock Forecast, Price & News

$0.58
0.00 (-0.60%)
(As of 11/29/2021 01:31 PM ET)
Add
Compare
Today's Range
$0.58
$0.59
50-Day Range
$0.58
$0.70
52-Week Range
$0.55
$3.42
Volume
5,500 shs
Average Volume
3.93 million shs
Market Capitalization
$14.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.67
30 days | 90 days | 365 days | Advanced Chart
Receive SONN News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Sonnet BioTherapeutics logo

About Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SONN
Phone
N/A
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.22 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
23,235,000
Market Cap
$14.57 million
Optionable
Optionable

Company Calendar

Today
11/29/2021
Next Earnings (Estimated)
12/15/2021
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1254th out of 1,392 stocks

Pharmaceutical Preparations Industry

604th out of 670 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Sonnet BioTherapeutics (NASDAQ:SONN) Frequently Asked Questions

Is Sonnet BioTherapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Sonnet BioTherapeutics stock.
View analyst ratings for Sonnet BioTherapeutics
or view top-rated stocks.

Are investors shorting Sonnet BioTherapeutics?

Sonnet BioTherapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,090,000 shares, an increase of 123.0% from the October 31st total of 488,700 shares. Based on an average trading volume of 6,770,000 shares, the short-interest ratio is currently 0.2 days.
View Sonnet BioTherapeutics' Short Interest
.

When is Sonnet BioTherapeutics' next earnings date?

Sonnet BioTherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, December 15th 2021.
View our earnings forecast for Sonnet BioTherapeutics
.

Who are Sonnet BioTherapeutics' key executives?

Sonnet BioTherapeutics' management team includes the following people:
  • Dr. Pankaj Mohan, Founder, Chairman. CEO & Pres (Age 56, Pay $733.95k) (LinkedIn Profile)
  • Dr. John K. Cini Ph.D., Chief Scientific Officer & Co-Founder (Age 69, Pay $388.74k)
  • Mr. Jay Cross, Chief Financial Officer (Age 51, Pay $421.06k)
  • Ms. Susan Dexter, Chief Technical Officer (Age 66)
  • Dr. Richard T. Kenney, Chief Medical Officer (Age 63) (LinkedIn Profile)
  • Mr. Manuel Dafonseca, Head of Clinical Operations

What other stocks do shareholders of Sonnet BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), iBio (IBIO), Trevena (TRVN), Vaxart (VXRT), ADMA Biologics (ADMA) and Advanced Micro Devices (AMD).

What is Sonnet BioTherapeutics' stock symbol?

Sonnet BioTherapeutics trades on the NASDAQ under the ticker symbol "SONN."

Who are Sonnet BioTherapeutics' major shareholders?

Sonnet BioTherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.99%). Company insiders that own Sonnet BioTherapeutics stock include Albert D Dyrness, Pankaj Mohan and Richard T Kenney.
View institutional ownership trends for Sonnet BioTherapeutics
.

Which institutional investors are buying Sonnet BioTherapeutics stock?

SONN stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. Company insiders that have bought Sonnet BioTherapeutics stock in the last two years include Albert D Dyrness, Pankaj Mohan, and Richard T Kenney.
View insider buying and selling activity for Sonnet BioTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Sonnet BioTherapeutics?

Shares of SONN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sonnet BioTherapeutics' stock price today?

One share of SONN stock can currently be purchased for approximately $0.58.

How much money does Sonnet BioTherapeutics make?

Sonnet BioTherapeutics has a market capitalization of $14.57 million.

How many employees does Sonnet BioTherapeutics have?

Sonnet BioTherapeutics employs 8 workers across the globe.

What is Sonnet BioTherapeutics' official website?

The official website for Sonnet BioTherapeutics is www.chanticleerholdings.com.

Where are Sonnet BioTherapeutics' headquarters?

Sonnet BioTherapeutics is headquartered at 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540.

How can I contact Sonnet BioTherapeutics?

Sonnet BioTherapeutics' mailing address is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. The company can be reached via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.